February 25, 2021
Now available UKONIQ™
UKONIQ™ (umbralisib) is a kinase inhibitor indicated for the treatment of adult patients with:
• Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen
• Relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy